{"title":"治疗性单克隆抗体和片段:雷尼单抗。","authors":"Adiel G Smith, Peter K Kaiser","doi":"10.1159/000431200","DOIUrl":null,"url":null,"abstract":"<p><p>Ranibizumab is a recombinant, humanized, affinity-matured, monoclonal antibody Fab fragment against all isoforms of vascular endothelial growth factor-A, which was developed specifically for intraocular use. Ranibizumab has been extensively investigated in clinical trials on choroidal neovascularization from wet age-related macular degeneration and pathologic myopia, as well as macular edema due to diabetic retinopathy and retinal vein occlusion. Numerous randomized, controlled clinical trials have shown this medication to be effective in improving both vision as well as anatomical outcomes, and the medication has repeatedly shown to have an acceptable safety profile.</p>","PeriodicalId":77107,"journal":{"name":"Developments in ophthalmology","volume":"55 ","pages":"246-51"},"PeriodicalIF":0.0000,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000431200","citationCount":"7","resultStr":"{\"title\":\"Therapeutic Monoclonal Antibodies and Fragments: Ranibizumab.\",\"authors\":\"Adiel G Smith, Peter K Kaiser\",\"doi\":\"10.1159/000431200\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Ranibizumab is a recombinant, humanized, affinity-matured, monoclonal antibody Fab fragment against all isoforms of vascular endothelial growth factor-A, which was developed specifically for intraocular use. Ranibizumab has been extensively investigated in clinical trials on choroidal neovascularization from wet age-related macular degeneration and pathologic myopia, as well as macular edema due to diabetic retinopathy and retinal vein occlusion. Numerous randomized, controlled clinical trials have shown this medication to be effective in improving both vision as well as anatomical outcomes, and the medication has repeatedly shown to have an acceptable safety profile.</p>\",\"PeriodicalId\":77107,\"journal\":{\"name\":\"Developments in ophthalmology\",\"volume\":\"55 \",\"pages\":\"246-51\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1159/000431200\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Developments in ophthalmology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000431200\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2015/10/26 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Developments in ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000431200","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2015/10/26 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Therapeutic Monoclonal Antibodies and Fragments: Ranibizumab.
Ranibizumab is a recombinant, humanized, affinity-matured, monoclonal antibody Fab fragment against all isoforms of vascular endothelial growth factor-A, which was developed specifically for intraocular use. Ranibizumab has been extensively investigated in clinical trials on choroidal neovascularization from wet age-related macular degeneration and pathologic myopia, as well as macular edema due to diabetic retinopathy and retinal vein occlusion. Numerous randomized, controlled clinical trials have shown this medication to be effective in improving both vision as well as anatomical outcomes, and the medication has repeatedly shown to have an acceptable safety profile.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
